Cooper Companies, Inc. (COO) Stock Analysis and Metrics

Cooper Companies

NASDAQ: COO

$70.31 ▲ +0.08 (+0.11%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap13.77 Bn

P/E58.38

P/S3.25

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)2.46 Bn

Revenue Growth (1y) (Qtr)7.90

Add ratio to table…

About

THE COOPER COMPANIES, INC. designs, manufactures, and markets medical devices focused on vision care and women's health. The company conducts its business through subsidiaries located in the Americas, Europe, Middle East, Africa, and Asia Pacific. Its core activities include the production of soft contact lenses and a diversified portfolio of surgical devices, cryostorage solutions, contraceptive products, and fertility diagnostics and treatments. THE COOPER COMPANIES, INC. sells its products to eye care practitioners, hospitals, ambulatory surgery centers, medical offices, fertility clinics, and retail distributors worldwide.

The company generates revenue primarily from the sale of its contact lenses and women's health products. In the 3 months ended January 31, 2026, CooperVision reported net sales of $695.1 million, comprising $351.2 million from toric and multifocal lenses and $343.9 million from spherical and other lenses. Within CooperVision, toric and multifocal sales grew 10% year over year driven by MyDay and Biofinity, while spherical and other sales increased 5% due to demand for MiSight, Biofinity, and MyDay products. CooperSurgical generated net sales of $329.0 million in the same period, with $202.4 million from office and surgical offerings and $126.6 million from fertility offerings. Office and surgical revenue includes surgical devices, cryostorage for cord blood and tissue, and contraception products, which rose 2% due to higher surgical device sales. Fertility revenue encompasses diagnostics, consumables, equipment, donor gamete services, and genetic testing, increasing 6% as a result of greater demand for consumable products. These products are sold to eye care professionals, hospitals, ambulatory surgery centers, medical offices, fertility clinics, and patients seeking assisted reproductive care.

The company operates through the following segments.

• CooperVision: This segment designs, manufactures, and distributes soft contact lenses including spherical, toric, multifocal, and myopia management lenses made from silicone hydrogel materials such as Aquaform and ActivControl, with product families like clariti, MyDay, MyDay Energys, Biofinity, Avaira Vitality, and the FDA approved MiSight 1 day lens aimed at slowing myopia progression in children aged 8 to 12.

• CooperSurgical: This segment provides a diversified portfolio of products and services for fertility and women's health care, encompassing surgical devices for gynecologic procedures, cryostorage solutions for cord blood and tissue, contraceptive offerings such as Paragard, and fertility solutions that include diagnostics, consumables, equipment, donor gamete services, and genetic testing to support in vitro fertilization and assisted reproductive technologies.

In the global contact lens market, THE COOPER COMPANIES, INC. competes with major players such as Johnson & Johnson Vision, Alcon, and Bausch + Lomb, maintaining a strong position through its proprietary silicone hydrogel technologies and innovative myopia management portfolio. The company's advantages include its Aquaform and ActivControl lens materials, the FDA approved MiSight 1 day lens, and a broad distribution network that reaches eye care professionals in over 100 countries. In the fertility and women's health sector, CooperSurgical faces competition from companies like Hologic and CooperSurgical's integrated suite of surgical tools, cryostorage, contraception, and fertility diagnostics provides a differentiated offering that appeals to hospitals, clinics, and physicians seeking comprehensive reproductive health solutions.

THE COOPER COMPANIES, INC.'s customer base comprises optometrists and ophthalmologists who prescribe its contact lenses to end users, as well as retail distributors and pharmacies that dispense the lenses to consumers. CooperSurgical serves hospitals, ambulatory surgery centers, medical offices, obstetricians and gynecologists, fertility clinics, and patients undergoing assisted reproductive treatments such as in vitro fertilization and intrauterine insemination.

Investment Thesis

▲ Bull case

CooperVision's MyDay MySight platform represents a significant, underappreciated growth engine that is gaining traction faster than the market realizes, particularly in Japan, where myopia prevalence among elementary school children is estimated at 77%, creating a massive addressable market for the only FDA-approved contact lens for myopia control in both Japan and China; the recent launch of MyDay MiSight in Japan in February received an enthusiastic response, and the company is supporting this with comprehensive professional engagement programs, including high-impact regional launch events and extensive KOL education, which are driving strong clinician activation rates that will sustain long-term double-digit growth beyond the current 23% quarterly increase, positioning MiSight to become a multi-year, high-margin growth driver that offsets slower legacy hydrogel trends in Asia Pac. The MADE BETTER™ Promise sustainability initiative, while not prominently featured in earnings guidance, is a hidden catalyst that enhances brand differentiation and customer loyalty in key markets like EMEA and North America, where eye care professionals and end-users increasingly prioritize environmentally responsible suppliers; by integrating ISCC PLUS-certified bio-attributed materials, lower-carbon manufacturing processes, and a plastic neutrality program that has already recycled over 659 million plastic bottles, CooperVision is future-proofing its premium MyDay line against regulatory and reputational risks while potentially enabling premium pricing power, a factor not yet reflected in current organic growth rates but poised to accelerate adoption as sustainability becomes a decisive factor in purchasing decisions. CooperSurgical's fertility business is experiencing a structural recovery that management understated, with improving IVF cycles in the U.S. and several European countries, renewed clinic interest in adopting new technologies, and early signs of market stabilization after a prolonged downturn; despite acknowledging softness in The Middle East, the company noted steady improvement through the first quarter driven by solid execution on contract wins and new product launches, and the fertility segment's recovery is being driven by fundamental demand normalization rather than temporary stimulus, suggesting multi-year growth potential that could lift CooperSurgical's organic growth trajectory beyond the guided 4% to 5% range as the business leverages its leading market position in fertility genomics and specialized surgical devices. The company's capital allocation discipline, including the repurchase of $92 million in stock during Q1 and the extension of $950 million of its term loan to February 2031, reflects a strong balance sheet and management's confidence in sustained free cash flow generation, which is being underestimated by the market; with free cash flow guidance raised to $600–$625 million for FY26 and a trajectory to generate over $2.2 billion in free cash flow from FY26 through FY28, Cooper has significant flexibility to accelerate share buybacks, fund strategic acquisitions, or increase R&D investment in high-return areas like myopia control innovation (e.g., MyDay MiSight toric and atropine combinations), all of which could drive incremental EPS growth beyond the raised guidance of $4.58–$4.66.

CooperVision's MyDay MySight platform represents a significant, underappreciated growth engine that is gaining traction faster than the market realizes, particularly in Japan, where myopia prevalence among elementary school children is estimated at 77%, creating a massive addressable market for the only FDA-approved contact lens for myopia control in both Japan and China; the recent launch of MyDay MiSight in Japan in February received an enthusiastic response, and the company is supporting this with comprehensive professional engagement programs, including high-impact regional launch events and extensive KOL education, which are driving strong clinician activation rates that will sustain long-term double-digit growth beyond the current 23% quarterly increase, positioning MiSight to become a multi-year, high-margin growth driver that offsets slower legacy hydrogel trends in Asia Pac. The MADE BETTER™ Promise sustainability initiative, while not prominently featured in earnings guidance, is a hidden catalyst that enhances brand differentiation and customer loyalty in key markets like EMEA and North America, where eye care professionals and end-users increasingly prioritize environmentally responsible suppliers; by integrating ISCC PLUS-certified bio-attributed materials, lower-carbon manufacturing processes, and a plastic neutrality program that has already recycled over 659 million plastic bottles, CooperVision is future-proofing its premium MyDay line against regulatory and reputational risks while potentially enabling premium pricing power, a factor not yet reflected in current organic growth rates but poised to accelerate adoption as sustainability becomes a decisive factor in purchasing decisions. CooperSurgical's fertility business is experiencing a structural recovery that management understated, with improving IVF cycles in the U.S. and several European countries, renewed clinic interest in adopting new technologies, and early signs of market stabilization after a prolonged downturn; despite acknowledging softness in The Middle East, the company noted steady improvement through the first quarter driven by solid execution on contract wins and new product launches, and the fertility segment's recovery is being driven by fundamental demand normalization rather than temporary stimulus, suggesting multi-year growth potential that could lift CooperSurgical's organic growth trajectory beyond the guided 4% to 5% range as the business leverages its leading market position in fertility genomics and specialized surgical devices. The company's capital allocation discipline, including the repurchase of $92 million in stock during Q1 and the extension of $950 million of its term loan to February 2031, reflects a strong balance sheet and management's confidence in sustained free cash flow generation, which is being underestimated by the market; with free cash flow guidance raised to $600–$625 million for FY26 and a trajectory to generate over $2.2 billion in free cash flow from FY26 through FY28, Cooper has significant flexibility to accelerate share buybacks, fund strategic acquisitions, or increase R&D investment in high-return areas like myopia control innovation (e.g., MyDay MiSight toric and atropine combinations), all of which could drive incremental EPS growth beyond the raised guidance of $4.58–$4.66.

▼ Bear case

CooperVision's organic growth remains overly dependent on the Americas and EMEA, with Asia Pac declining 4% in Q1 due to persistent weakness in legacy hydrogel products in Japan, a trend management acknowledged will likely continue into Q2, and while product launches like MyDay toric and MiSight are progressing, the transition to these premium offerings is not occurring fast enough to offset the decline in lower-margin, high-volume older hydrogel sales, suggesting that the region's return to growth in Q3 is contingent on execution risk and may be delayed if competitor gains in traditional hydrogels persist, thereby creating a structural drag on consolidated organic growth that could keep it below the guided 2.9% to 3.3% range for longer than anticipated. Despite strong MyDay multifocal and MiSight growth, the company's premiumization strategy faces headwinds from intense competition in the daily silicone hydrogel category, where rivals are launching competitively priced full-family silicone hydrogel upgrade paths (such as the planned clariti family launch in Japan later this year), which could erode CooperVision's market share gains and limit its ability to sustain above-market growth, particularly as the company admitted it has not caved on price in Japan but is still losing share to competitors on older hydrogel products, indicating that pricing power may be weaker than implied by its premium product performance and that volume-driven growth in commoditized segments remains elusive. CooperSurgical's fertility recovery, while showing early signs of improvement, remains fragile and highly sensitive to geopolitical risks, with The Middle East accounting for approximately 2% of consolidated sales and representing a region where CooperSurgical holds a leading market position but faces significant distribution challenges due to ongoing conflict; management admitted that if the situation extends, it will be more challenging to get product to market, and while fertility clinics in the U.S. and Europe are showing renewed interest in new technology, the lack of a fast, huge ramp-up in IVF cycles suggests the recovery is tentative and could reverse if macroeconomic or regional instability worsens, making the fertility segment's improvement less durable than implied by management's commentary. The company's operating margin expansion, while impressive in Q1, is heavily reliant on the benefits of last year's reorganization and AI-driven efficiencies, which may be nearing the end of their incremental contribution, with operating expenses already roughly flat year over year and limited scope for further significant reductions without impacting core operations; as the multi-year CapEx cycle winds down, the potential for material gains from next-generation production improvements remains uncertain and early-stage, meaning that future margin expansion will depend more on volatile top-line growth rather than structural cost savings, raising concerns about the sustainability of the raised EPS guidance of $4.58–$4.66 if revenue growth disappoints.

CooperVision's organic growth remains overly dependent on the Americas and EMEA, with Asia Pac declining 4% in Q1 due to persistent weakness in legacy hydrogel products in Japan, a trend management acknowledged will likely continue into Q2, and while product launches like MyDay toric and MiSight are progressing, the transition to these premium offerings is not occurring fast enough to offset the decline in lower-margin, high-volume older hydrogel sales, suggesting that the region's return to growth in Q3 is contingent on execution risk and may be delayed if competitor gains in traditional hydrogels persist, thereby creating a structural drag on consolidated organic growth that could keep it below the guided 2.9% to 3.3% range for longer than anticipated. Despite strong MyDay multifocal and MiSight growth, the company's premiumization strategy faces headwinds from intense competition in the daily silicone hydrogel category, where rivals are launching competitively priced full-family silicone hydrogel upgrade paths (such as the planned clariti family launch in Japan later this year), which could erode CooperVision's market share gains and limit its ability to sustain above-market growth, particularly as the company admitted it has not caved on price in Japan but is still losing share to competitors on older hydrogel products, indicating that pricing power may be weaker than implied by its premium product performance and that volume-driven growth in commoditized segments remains elusive. CooperSurgical's fertility recovery, while showing early signs of improvement, remains fragile and highly sensitive to geopolitical risks, with The Middle East accounting for approximately 2% of consolidated sales and representing a region where CooperSurgical holds a leading market position but faces significant distribution challenges due to ongoing conflict; management admitted that if the situation extends, it will be more challenging to get product to market, and while fertility clinics in the U.S. and Europe are showing renewed interest in new technology, the lack of a fast, huge ramp-up in IVF cycles suggests the recovery is tentative and could reverse if macroeconomic or regional instability worsens, making the fertility segment's improvement less durable than implied by management's commentary. The company's operating margin expansion, while impressive in Q1, is heavily reliant on the benefits of last year's reorganization and AI-driven efficiencies, which may be nearing the end of their incremental contribution, with operating expenses already roughly flat year over year and limited scope for further significant reductions without impacting core operations; as the multi-year CapEx cycle winds down, the potential for material gains from next-generation production improvements remains uncertain and early-stage, meaning that future margin expansion will depend more on volatile top-line growth rather than structural cost savings, raising concerns about the sustainability of the raised EPS guidance of $4.58–$4.66 if revenue growth disappoints.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password